ENvue Medical, Inc.
NCM: FEEDLive Quote
📈 ZcoreAI Score
Our AI model analyzes ENvue Medical, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get FEED Z-Score →About ENvue Medical, Inc.
Healthcare
Medical Devices
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. ENvue Medical, Inc. was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Arlington Heights, Illinois.
📊 Fundamental Analysis
ENvue Medical, Inc. demonstrates a profit margin of -251.9%, which is below the sector average, suggesting competitive pressure.
The company recently reported 92.0% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -30.5%, which indicates that capital utilization is currently under pressure.
At a current price of $1.66, FEED currently trades near the bottom of its 52-week range (1%), indicating potential value or weakness (Range: $0.99 - $88.20).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$1.81M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
2.10
52W High
$88.20
52W Low
$0.99
Avg Volume
12.82M
Day High
Day Low